ClinicalTrials.gg
RecruitingNCT07521631Updated Apr 13, 2026

Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes

A Phase 2 interventional study of HDM1005 dose level 1 and HDM1005 dose level 2 in Obesity, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
372
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Obesity by Huadong Medicine Co., Ltd. — 10 open to participants now, 11 under way, 5 of them phase 3. Obesity · Huadong Medicine Co., Ltd..

Planned enrollment
4th of 13
372 · median 200
Started
2026
with 5 others
Phase 2
3 of 13
3 open now
Primary completion
2027-02
later than 8 of 10 live
Registered
9th of 13
by date

Among the 13 studies in Obesity by Huadong Medicine Co., Ltd., this one is the 4th largest by planned enrollment, is one of 6 that started in 2026, is one of 3 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 9th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

10 of the 13 studies in Obesity by Huadong Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Obesity by Huadong Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is a 56-week randomized, open-label, controlled study evaluating the efficacy and safety of the HDM1005 compared to tirzepatide in adults with obesity but without diabetes. Eligible participants will be screened and randomized to different dose group of HDM1005 or the tirzepatide group at a ratio of 1:1:1 :1, HDM1005 or tirzepatide will be given once weekly for 52 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that involved counselling on diet and physical activity.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The age of signing ICF was from 18 to 65 years old (including both ends), regardless of gender.
  2. ≥28.0 but \<40.0 kg/m2 at screening and randomization
  3. Participants reported that they had been under diet and exercise control for 3 months or more before screening, and their weight change (the difference between the maximum body weight and the minimum body weight) in the past 3 months was less than 5%.
  4. fertile female subjects who have taken and agreed to continue to take effective measures from 14 days before signing ICF to 60 days after the last dose, and have no plans to give birth and donate eggs; Male subjects signed ICF until 90 days after the last dose, had no fertility plan and sperm donation plan, and agreed to use highly effective contraception.

Exclusion criteria

Exclusion Criteria:

  1. Previous diagnosis of type 1, type 2, or any other type of diabetes.
  2. History or family history of medullary thyroid carcinoma, C cell hyperplasia, or multiple endocrine neoplasia type
  3. According to the investigator's judgment, the subjects have endocrine diseases or histories that affect gastric emptying, may significantly affect body weight, or diseases or conditions that affect the absorption of gastrointestinal nutrients, such as Cushing syndrome, hypothyroidism or hyperthyroidism, bariatric surgery or other gastrectomy, irritable bowel syndrome, dyspepsia, and chronic pancreatitis; Or a history of acute pancreatitis or acute gallbladder disease within 3 months before signing ICF.
  4. Hypertension that was not stably controlled at screening: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg (with stable treatment for at least 30 days if antihypertensive medications were used).

    Have any malignant tumor within 5 years before signing ICF (except basal cell carcinoma which has received curative treatment and is regarded as cured).

  5. Those who had severe infection, severe trauma, or large or medium-sized surgery within 3 months before signing ICF, or planned to undergo surgery during the study (except outpatient surgery).
  6. Previous or combined presence or suspicion of depression or other psychiatric disorders or screening PHQ-9 score ≥15.
  7. Known intolerance or allergy to any component of the study drug or glucagon-like peptide-1 receptor (GLP-1R) agonist, or a previous history of severe drug allergy.
  8. Use of any of the following drugs, products, or treatments within 3 months prior to signing the ICF, including but not limited to:

    A. a drug, product or treatment with weight loss effect b. Medications, products, or treatments that significantly increase body weight

  9. Use of hypoglycemic drugs within 3 months before signing ICF.
  10. Have participated in any clinical trial within 3 months before signing ICF or within 5 half-lives (whichever is longer) after the last dose of the drug used in the clinical trial (except for those who signed ICF without drug or device intervention).
  11. History of addictive drug abuse within 1 year before signing ICF.
  12. Estimated (eGFR) according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation \<60 mL/min/1.73 m2;
  13. Those who donated blood or lost ≥400 mL of total blood within 3 months before signing ICF, or received blood transfusion or used blood products, or planned to donate blood during the study period.
  14. Pregnant or lactating women.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
372 participants (estimated)

Study arms

  • Experimental
    HDM1005 injection dose group 1

    Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose, the intervention will last for 52 weeks in total.

    Drug: HDM1005 dose level 1

  • Experimental
    HDM1005 injection dose group 2

    Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose, the intervention will last for 52 weeks in total.

    Drug: HDM1005 dose level 2

  • Experimental
    HDM1005 injection dose group 3

    Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose, the intervention will last for 52 weeks in total.

    Drug: HDM1005 dose level 3

  • Active comparator
    tirzepatide injection

    Initiate at a once weekly dose of 2.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose, the intervention will last for 52 weeks in total.

    Drug: Tirzepatide

Interventions

  • Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose level 1, the intervention will last for 52 weeks in total.

  • Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose level 2, the intervention will last for 52 weeks in total.

  • Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose level 3, the intervention will last for 52 weeks in total.

  • Initiate at a once weekly dose of 2.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose, the intervention will last for 52 weeks in total.

06

What researchers measure

Primary outcomes

  1. Primary Outcome

    The percentage change in body weight from baseline to week 40

    Time frame: week 40

Secondary outcomes

  1. Secondary Outcome

    The proportion of participants reaching a body weight loss of at least 5%, 10% and 15% at week 40

    Time frame: week 40

  2. Secondary Outcome

    The percentage change in body weight from baseline to week 52

    Time frame: week 52

  3. Secondary Outcome

    Change in waist circumference at week 40

    Time frame: week 40

  4. Secondary Outcome

    Change in body weight at week 40

    Time frame: week 40

  5. Secondary Outcome

    Change in BMI at week 40

    Time frame: week 40

  6. Secondary Outcome

    Change in BMI at week 52

    Time frame: week 52

  7. Secondary Outcome

    Change in waist circumference at week 52

    Time frame: week 52

  8. Secondary Outcome

    Change in waist body weight at week 52

    Time frame: week 52

  9. Secondary Outcome

    Change in systolic blood pressure (SBP) at week 40

    Time frame: week 40

  10. Secondary Outcome

    Change in diastolic blood pressure (DBP) at week 40

    Time frame: week 40

  11. Secondary Outcome

    Change in lipids at week 40

    Time frame: week 40

  12. Secondary Outcome

    Change in SBP at week 52

    Time frame: week 52

  13. Secondary Outcome

    Change in DBP at week 52

    Time frame: week 52

  14. Secondary Outcome

    Change in lipids at week 52

    Time frame: week 52

  15. Safety Outcome

    the incidence of adverse events

    Time frame: week 52

  16. Immunogenicity Outcome

    ADA and NAb

    Time frame: week 52

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 10 months after the start.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 10 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 13, 2026
StartActual
Mar 31, 2026
Primary completionEst.
Feb 4, 2027
CompletionEst.
Jul 23, 2027
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07521631
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Mar 31, 2026
Primary completion
Feb 4, 2027 (estimated)
Completion
Jul 23, 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

Ling Tao
Contact
cxytaoling@eastchinapharm.com
+86 021-64041990
Xiaoying Li, Medical doctor
principal investigator · Shanghai Zhongshan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HDM1005

Start the discussion